Red Light Therapy for Myopia Control: Parent's Guide

Repeated low-level red light (RLRL) therapy has moved from a curiosity to a genuine clinical option in a remarkably short time. Across Singapore, Hong Kong, and China, some optometrists are already recommending it to parents whose children are progressing rapidly — or who haven't responded well to atropine or orthokeratology. Other practitioners are still waiting for more data.

If your child has myopia and you've started hearing about "red light therapy," this guide explains what it is, what the evidence actually shows, who it might suit, and what to ask if you're considering it as part of your child's myopia control plan.

What Is Red Light Therapy for Myopia?

Red light therapy for myopia — also called repeated low-level red light (RLRL) therapy or low-level light therapy (LLLT) — involves exposing a child's eyes to a low-intensity beam of red light, typically at a wavelength around 650 nanometres. The child looks into a handheld or tabletop device for approximately three minutes per session, twice daily, five days a week.

This is not the same as laser treatment, photodynamic therapy, or the red-light devices marketed for skin rejuvenation in wellness clinics. The wavelengths, intensities, and biological targets are entirely different. Myopia RLRL devices emit far less energy than a laser and are designed specifically to stimulate the retina at safe, therapeutic levels.

The concept emerged from laboratory and animal research showing that retinal exposure to certain light wavelengths could influence eye growth — the same biological principle that explains why children who spend more time outdoors develop myopia at lower rates. Natural outdoor light is bright and spectrally rich; RLRL attempts to deliver a targeted slice of that stimulus in a controlled, repeatable dose.

The Evidence So Far

Key Clinical Trials

The bulk of the clinical evidence comes from researchers in mainland China, where myopia rates are among the highest in the world and where the devices have regulatory approval for use in children.

Jiang et al. (2022), Ophthalmology: This randomised controlled trial enrolled 264 children aged 8–13 in China, comparing RLRL therapy (using a device from CREWT Medical Systems) against a control group wearing single-vision spectacles. After 12 months, axial elongation — the physical lengthening of the eyeball that drives myopia — was 0.13 mm in the treatment group compared to 0.38 mm in controls, roughly a 65–70% reduction. Spherical equivalent progression was similarly slowed. No significant adverse effects on visual acuity, contrast sensitivity, or retinal structure were detected.

24-month follow-up data (2023–2024): Follow-up research from similar cohorts found that the treatment effect was sustained over two years when therapy was continued, with choroidal thickening (a measurable sign of reduced eye elongation) persisting throughout. Children who stopped treatment after 12 months showed some rebound — a pattern seen with other myopia control modalities as well.

Multiple smaller trials (2021–2024): Several single-centre and multi-centre studies from Zhongshan Ophthalmic Center, Sun Yat-Sen University, and other leading Chinese institutions have broadly replicated these results, with reported reductions in axial elongation ranging from 40% to over 70% depending on age, baseline myopia severity, and treatment adherence.

What the Numbers Mean in Practice

A 65% reduction in axial elongation is a large effect — larger, on average, than low-dose (0.01%) atropine alone, and comparable to orthokeratology in some trial populations. This has generated significant excitement in the optometry community.

However, a few important caveats apply:

Most trials are from China. The vast majority of RLRL research has been conducted in Chinese populations with Chinese-manufactured devices. Replication in other populations and with other devices is still limited. Real-world generalisation across ethnicities should be treated with caution until broader data emerge.

Trial populations are relatively narrow. Many published trials enrolled children aged 6–14 with moderate myopia. Evidence for very young children (under 6), high myopes (over −6.00 D), and adolescents approaching the end of their growth period is thinner.

Adherence matters enormously. Per-protocol analyses in most trials show stronger effects than intention-to-treat analyses, suggesting that children who consistently use the device twice daily see the best outcomes. A child who uses the device irregularly will likely see reduced benefit.

Long-term safety beyond two years is still being established. The available safety data are reassuring — no trial has reported retinal damage at the doses used — but two years is not a long time when treating a condition that begins at age 7 and continues through adolescence.

How RLRL Therapy Works: The Proposed Mechanism

Researchers are not yet certain exactly how red light slows myopia progression, and several mechanisms likely contribute.

The leading hypothesis centres on the retina's photoreceptors and a cascade effect that increases choroidal thickness — the thickness of the highly vascular layer of tissue behind the retina. A thicker choroid is associated with slower eye growth, and RLRL therapy consistently produces measurable increases in choroidal thickness, visible on optical coherence tomography (OCT) imaging. This is similar to the choroidal response seen with high concentrations of atropine and with orthokeratology.

A second proposed pathway involves retinal dopamine. Outdoor light triggers dopamine release from retinal amacrine cells, and dopamine is a known inhibitor of eye elongation. Red light at therapeutic wavelengths may stimulate a similar dopaminergic response.

A third possibility is direct stimulation of mitochondrial photoreceptors in retinal cells via cytochrome c oxidase, triggering cellular changes that influence scleral remodelling and eye growth signalling.

What all three pathways share is a biological plausibility rooted in the broader science of light and eye development — which is part of what makes RLRL therapy scientifically credible, even as the precise mechanism remains under investigation.

RLRL Therapy vs Other Myopia Control Options

How does red light therapy compare to established treatments? The table below summarises the evidence roughly, though direct head-to-head trials are still limited.

Treatment	Typical axial elongation reduction	Requires clinical procedure?	Daily burden
Low-dose atropine (0.01%)	~30–50%	No (eye drops at home)	1 drop nightly
Orthokeratology	~40–60%	Yes (fitting, ongoing checks)	Nightly lens wear
DIMS/HALT spectacle lenses	~40–60%	No (standard dispensing)	Full-time wear
MiSight contact lenses	~40–52%	Yes (fitting)	Daily lens wear
RLRL therapy	~50–70%	Minimal (device use at home)	2 × 3 min/day

RLRL therapy's efficacy profile sits at or near the top of the available options in published trial data. Its practical advantage over orthokeratology is that it involves no overnight lens wear — important for families who are concerned about contact lens handling in young children. Its advantage over spectacle-based options is that it can be added as an adjunct, potentially stacking efficacy.

Some Singapore and Hong Kong optometrists are now combining RLRL therapy with low-dose atropine for children with aggressive myopia progression, though robust combination-therapy trial data are still limited.

Is It Right for Every Child?

No. RLRL therapy is generally considered most appropriate for:

Children aged 6–14 with documented myopia progression
Those who have not achieved adequate control with spectacle lenses alone
Families who prefer to avoid contact lens wear (ruling out orthokeratology or MiSight)
Children who experience side effects from atropine (though atropine remains an option in combination)

It is less well-studied and generally not recommended as a first-line option for:

Very young children (under 6) without an optometrist's guidance
Children with photosensitivity conditions or retinal disease
Those unable to comply with the twice-daily protocol

Availability in Singapore

RLRL therapy is available at a growing number of optometry clinics and eye care centres in Singapore, though it is not yet as widely available as atropine prescriptions or orthokeratology fitting. Availability is higher in private specialist eye clinics and some independent optometry practices that have invested in the technology.

The devices approved for use in Singapore vary; ask your optometrist which device they use, what the clinical evidence is for that specific device, and whether any local practitioners have trained in its use.

Because the category is still emerging, fee structures vary considerably. Some clinics offer the device for supervised in-clinic sessions; others provide a device for home use, either purchased or rented. Typical home-use costs in the region have ranged from SGD $1,500–$4,000 for a device, though this is subject to change as market competition increases.

Safety: What Parents Should Know

The safety profile of RLRL therapy in published trials has been reassuring. Key findings from safety analyses include:

No reported cases of retinal damage in any published trial at therapeutic doses
Contrast sensitivity and colour vision unaffected in trials up to 24 months
Best-corrected visual acuity maintained in treatment groups
Mild transient photophobia (light sensitivity) reported in a small proportion of children, typically resolving without intervention

That said, parents should be aware of what is not yet known. Long-term safety data beyond two years remain limited. The specific devices used in trials (primarily CREWT's device) have been studied more rigorously than some others now entering the market. Not all devices marketed as "myopia red light therapy" are equivalent — the wavelength, intensity, and treatment protocol matter significantly.

If you are considering RLRL therapy for your child, insist on:

A device with published peer-reviewed trial data behind it
An optometrist who conducts baseline imaging (ideally OCT) before starting therapy
Regular monitoring appointments (every 3–6 months) to track axial length and check for any changes in retinal health
Strict adherence to the prescribed protocol — more is not better

How to Talk to Your Optometrist About RLRL Therapy

If you are interested in exploring red light therapy for your child's myopia, come to the consultation prepared. Bring any previous records showing your child's prescription history over the past one to two years — progressive change over time is the most important indication for active myopia control.

Questions worth asking:

How much has my child's myopia progressed in the last 12 months, in both prescription (diopters) and axial length (millimetres)?
Which myopia control options are most appropriate given my child's age and rate of progression?
Does your clinic offer RLRL therapy, and which device do you use?
What monitoring protocol do you follow for children on RLRL therapy?
Would you consider combining RLRL therapy with another modality given my child's progression rate?

An evidence-based optometrist will not push any single treatment as universally superior. The right choice depends on your child's specific rate of progression, their age, their lifestyle, and your family's practical constraints around compliance.

Tracking Your Child's Myopia Progression

Regardless of which treatment your optometrist recommends, tracking progression accurately is essential. Axial length measurement (in millimetres) is now considered the gold standard for monitoring myopia control outcomes — more informative than prescription change alone because it directly measures the eye's physical growth.

If your child's current optometrist does not measure axial length at each visit, consider asking why and whether it might be added. Many clinics in Singapore now routinely include it in myopia management consultations.

To understand your child's current trajectory and what different control options might mean for their long-term prescription, try our free Myopia Progression Calculator. Enter your child's current age and prescription to see predicted progression to age 17 without treatment, and estimated outcomes with atropine, orthokeratology, and spectacle-based control options.

The Bottom Line

Red light therapy for myopia is not fringe science. It is backed by multiple randomised controlled trials showing real, measurable reductions in axial elongation — with an efficacy signal that has caught the attention of major academic eye care centres across Asia.

It is also not yet fully understood, not universally available, and not appropriate for every child. The science is evolving rapidly; what is true of the evidence base in 2025 will likely look different by 2027 as longer-term data and more diverse trial populations come in.

What has not changed — and will not change — is the importance of early action. Myopia progresses fastest in younger children, and the years between age 6 and 14 are when intervention has the greatest potential to limit long-term severity. Whether or not RLRL therapy turns out to be part of your child's plan, starting the conversation with your optometrist now is always the right move.

If you found this guide useful, explore our other myopia resources: the Myopia Risk Calculator to assess your child's risk profile, and our Eye Care Directory to find optometrists in Singapore who specialise in myopia management.